Last reviewed · How we verify
Femoral Nerve Catheters
At a glance
| Generic name | Femoral Nerve Catheters |
|---|---|
| Also known as | 0.5% ropivacaine bolus followed by 0.2% infusion |
| Sponsor | Eastern Maine Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension (PHASE4)
- Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Knee Surgery (NA)
- From Battlefield to Recovery: Continuous Regional Anaesthesia for War-Related Lower Limb Trauma
- Postoperative Pain and Analgesic Use After Total Knee Arthroplasty
- Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (NA)
- Performance of a Novel Concept for Internal Fixation of a Novel Peripheral Nerve Block Catheter (NA)
- Peripheral Nerve Blocks for Above-the-knee Amputations (PHASE4)
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Femoral Nerve Catheters CI brief — competitive landscape report
- Femoral Nerve Catheters updates RSS · CI watch RSS
- Eastern Maine Medical Center portfolio CI